Immunogenic and replicative properties of classical swine fever virus replicon particles modified to induce IFN-α/β and carry foreign genes

Vaccine

Volumn 29, Issue 7, 2011, Pages 1491-1503

  Suter, Rolf ^a   Summerfield, Artur ^a   Thomann Harwood, Lisa J ^a   McCullough, Kenneth C ^a   Tratschin, Jon Duri ^a   Ruggli, Nicolas ^a  

^a INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

Author keywords

Classical swine fever virus; Interferon ; Virus replicon particle

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; PESTIVIRUS VACCINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CISTRON; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA MODIFICATION; DRUG EFFICACY; EXPERIMENTAL PIG; GENE EXPRESSION; GENE INSERTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PESTIVIRUS INFECTION; PRIORITY JOURNAL; REPLICON; RNA REPLICATION; SECONDARY IMMUNE RESPONSE; SWINE DISEASE; T LYMPHOCYTE; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CELL LINE; CLASSICAL SWINE FEVER; CLASSICAL SWINE FEVER VIRUS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERON-ALPHA; INTERFERON-BETA; REPLICON; RNA, VIRAL; SWINE; T-LYMPHOCYTES; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 79151469085     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.026     Document Type: Article

References (67)

1. Khromykh A.A. Replicon-based vectors of positive strand RNA viruses. Curr Opin Mol Ther 2000, 2(5):555-569.
2. Pijlman G.P., Suhrbier A., Khromykh A.A. Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin Biol Ther 2006, 6(2):135-145.
3. Rayner J.O., Dryga S.A., Kamrud K.I. Alphavirus vectors and vaccination. Rev Med Virol 2002, 12(5):279-296.
4. Dudek T., Knipe D.M. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006, 344(1):230-239.
5. Mandl C.W. Flavivirus immunization with capsid-deletion mutants: basics, benefits, and barriers. Viral Immunol 2004, 17(4):461-472.
6. Thompson J.M., Whitmore A.C., Konopka J.L., Collier M.L., Richmond E.M., Davis N.L., et al. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci U S A 2006, 103(10):3722-3727.
7. Tonkin D.R., Jorquera P., Todd T., Beard C.W., Johnston R.E., Barro M. Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine 2010, 28(18):3238-3246.
8. Fauquet C.M., Mayo M.A., Maniloff J., Desselberger U., Ball L.A. Virus taxonomy: classification and nomenclature of viruses. Eighth report of the international committee on taxonomy of viruses 2005, Academic Press, San Diego, CA.
9. Behrens S.E., Grassmann C.W., Thiel H.J., Meyers G., Tautz N. Characterization of an autonomous subgenomic pestivirus RNA replicon. J Virol 1998, 72(3):2364-2372.
10. Moser C., Stettler P., Tratschin J.D., Hofmann M.A. Cytopathogenic and noncytopathogenic RNA replicons of classical swine fever virus. J Virol 1999, 73(9):7787-7794.
11. Tratschin J.D., Moser C., Ruggli N., Hofmann M.A. Classical swine fever virus leader proteinase Npro is not required for viral replication in cell culture. J Virol 1998, 72(9):7681-7684.
12. Stark R., Meyers G., Rümenapf T., Thiel H.J. Processing of pestivirus polyprotein: cleavage site between autoprotease and nucleocapsid protein of classical swine fever virus. J Virol 1993, 67(12):7088-7095.
13. Rümenapf T., Stark R., Heimann M., Thiel H.J. N-terminal protease of pestiviruses: identification of putative catalytic residues by site-directed mutagenesis. J Virol 1998, 72(3):2544-2547.
14. Gil L.H., Ansari I.H., Vassilev V., Liang D., Lai V.C., Zhong W., et al. The amino-terminal domain of bovine viral diarrhea virus Npro protein is necessary for alpha/beta interferon antagonism. J Virol 2006, 80(2):900-911.
15. La Rocca S.A., Herbert R.J., Crooke H., Drew T.W., Wileman T.E., Powell P.P. Loss of interferon regulatory factor 3 in cells infected with classical swine fever virus involves the N-terminal protease, Npro. J Virol 2005, 79(11):7239-7247.
16. Ruggli N., Bird B.H., Liu L., Bauhofer O., Tratschin J.D., Hofmann M.A. N(pro) of classical swine fever virus is an antagonist of double-stranded RNA-mediated apoptosis and IFN-alpha/beta induction. Virology 2005, 340(2):265-276.
17. Ruggli N., Tratschin J.D., Schweizer M., McCullough K.C., Hofmann M.A., Summerfield A. Classical swine fever virus interferes with cellular antiviral defense: evidence for a novel function of N(pro). J Virol 2003, 77(13):7645-7654.
18. Bauhofer O., Summerfield A., Sakoda Y., Tratschin J.D., Hofmann M.A., Ruggli N. Classical swine fever virus Npro interacts with interferon regulatory factor 3 and induces its proteasomal degradation. J Virol 2007, 81(7):3087-3096.
19. Hilton L., Moganeradj K., Zhang G., Chen Y.H., Randall R.E., McCauley J.W., et al. The Npro product of bovine viral diarrhea virus inhibits DNA binding by interferon regulatory factor 3 and targets it for proteasomal degradation. J Virol 2006, 80(23):11723-11732.
20. Seago J., Hilton L., Reid E., Doceul V., Jeyatheesan J., Moganeradj K., et al. The Npro product of classical swine fever virus and bovine viral diarrhea virus uses a conserved mechanism to target interferon regulatory factor-3. J Gen Virol 2007, 88(Pt 11):3002-3006.
21. Ruggli N., Summerfield A., Fiebach A.R., Guzylack-Piriou L., Bauhofer O., Lamm C.G., et al. Classical swine fever virus can remain virulent after specific elimination of the interferon regulatory factor 3-degrading function of Npro. J Virol 2009, 83(2):817-829.
22. Szymanski M.R., Fiebach A.R., Tratschin J.D., Gut M., Ramanujam V.M., Gottipati K., et al. Zinc binding in pestivirus N(pro) is required for interferon regulatory factor 3 interaction and degradation. J Mol Biol 2009, 391(2):438-449.
23. Ceppi M., de Bruin M.G., Seuberlich T., Balmelli C., Pascolo S., Ruggli N., et al. Identification of classical swine fever virus protein E2 as a target for cytotoxic T cells by using mRNA-transfected antigen-presenting cells. J Gen Virol 2005, 86(Pt 9):2525-2534.
24. van Rijn P.A., Miedema G.K., Wensvoort G., van Gennip H.G., Moormann R.J. Antigenic structure of envelope glycoprotein E1 of hog cholera virus. J Virol 1994, 68(6):3934-3942.
25. Weiland E., Stark R., Haas B., Rümenapf T., Meyers G., Thiel H.J. Pestivirus glycoprotein which induces neutralizing antibodies forms part of a disulfide-linked heterodimer. J Virol 1990, 64(8):3563-3569.
26. Maurer R., Stettler P., Ruggli N., Hofmann M.A., Tratschin J.D. Oronasal vaccination with classical swine fever virus (CSFV) replicon particles with either partial or complete deletion of the E2 gene induces partial protection against lethal challenge with highly virulent CSFV. Vaccine 2005, 23(25):3318-3328.
27. Weiland E., Ahl R., Stark R., Weiland F., Thiel H.J. A second envelope glycoprotein mediates neutralization of a pestivirus, hog cholera virus. J Virol 1992, 66(6):3677-3682.
28. Frey C.F., Bauhofer O., Ruggli N., Summerfield A., Hofmann M.A., Tratschin J.D. Classical swine fever virus replicon particles lacking the Erns gene: a potential marker vaccine for intradermal application. Vet Res 2006, 37(5):655-670.
29. van Gennip H.G., Bouma A., van Rijn P.A., Widjojoatmodjo M.N., Moormann R.J. Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV. Vaccine 2002, 20(11-12):1544-1556.
30. Widjojoatmodjo M.N., van Gennip H.G., Bouma A., van Rijn P.A., Moormann R.J. Classical swine fever virus E(rns) deletion mutants: trans-complementation and potential use as nontransmissible, modified, live-attenuated marker vaccines. J Virol 2000, 74(7):2973-2980.
31. Beer M., Reimann I., Hoffmann B., Depner K. Novel marker vaccines against classical swine fever. Vaccine 2007, 25(30):5665-5670.
32. Ganges L., Nunez J.I., Sobrino F., Borrego B., Fernandez-Borges N., Frias-Lepoureau M.T., et al. Recent advances in the development of recombinant vaccines against classical swine fever virus: cellular responses also play a role in protection. Vet J 2008, 177(2):169-177.
33. Moser C., Tratschin J.D., Hofmann M.A. A recombinant classical swine fever virus stably expresses a marker gene. J Virol 1998, 72(6):5318-5322.
34. Stettler P., Devos R., Moser C., Tratschin J.D., Hofmann M.A. Establishment and application of bicistronic classical swine fever virus genomes for foreign gene expression and complementation of E2 deletion mutants. Virus Res 2002, 85(2):173-185.
35. Kasza L., Shadduck J.A., Christofinis G.J. Establishment, viral susceptibility and biological characteristics of a swine kidney cell line SK-6. Res Vet Sci 1972, 13(1):46-51.
36. McCullough K.C., Basta S., Knötig S., Gerber H., Schaffner R., Kim Y.B., et al. Intermediate stages in monocyte-macrophage differentiation modulate phenotype and susceptibility to virus infection. Immunology 1999, 98(2):203-212.
37. Ruggli N., Tratschin J.D., Mittelholzer C., Hofmann M.A. Nucleotide sequence of classical swine fever virus strain Alfort/187 and transcription of infectious RNA from stably cloned full-length cDNA. J Virol 1996, 70(6):3478-3487.
38. Summerfield A., Horn M.P., Lozano G., Carrasco C.P., Atze K., McCullough K. C-kit positive porcine bone marrow progenitor cells identified and enriched using recombinant stem cell factor. J Immunol Methods 2003, 280(1-2):113-123.
39. Mittelholzer C., Moser C., Tratschin J.D., Hofmann M.A. Generation of cytopathogenic subgenomic RNA of classical swine fever virus in persistently infected porcine cell lines. Virus Res 1997, 51(2):125-137.
40. Greiser-Wilke I., Moennig V., Coulibaly C.O., Dahle J., Leder L., Liess B. Identification of conserved epitopes on a hog cholera virus protein. Arch Virol 1990, 111(3-4):213-225.
41. Fray M.D., Mann G.E., Charleston B. Validation of an Mx/CAT reporter gene assay for the quantification of bovine type-I interferon. J Immunol Methods 2001, 249(1-2):235-244.
42. Kitamura T., Takaku F., Miyajima A. IL-1 up-regulates the expression of cytokine receptors on a factor-dependent human hemopoietic cell line, TF-1. Int Immunol 1991, 3(6):571-577.
43. Summerfield A., Knötig S.M., McCullough K.C. Lymphocyte apoptosis during classical swine fever: implication of activation-induced cell death. J Virol 1998, 72(3):1853-1861.
44. Summerfield A., McCullough K.C. Porcine bone marrow myeloid cells: phenotype and adhesion molecule expression. J Leukoc Biol 1997, 62(2):176-185.
45. Greiser-Wilke I., Dittmar K.E., Liess B., Moennig V. Heterogeneous expression of the non-structural protein p80/p125 in cells infected with different pestiviruses. J Gen Virol 1992, 73(Pt 1):47-52.
46. Moser C., Ruggli N., Tratschin J.D., Hofmann M.A. Detection of antibodies against classical swine fever virus in swine sera by indirect ELISA using recombinant envelope glycoprotein E2. Vet Microbiol 1996, 51(1-2):41-53.
47. Wehrle F., Renzullo S., Faust A., Beer M., Kaden V., Hofmann M.A. Chimeric pestiviruses: candidates for live-attenuated classical swine fever marker vaccines. J Gen Virol 2007, 88(Pt 8):2247-2258.
48. Mittelholzer C., Moser C., Tratschin J.D., Hofmann M.A. Analysis of classical swine fever virus replication kinetics allows differentiation of highly virulent from avirulent strains. Vet Microbiol 2000, 74(4):293-308.
49. Laval F., Paillot R., Bollard S., Fischer L., Audonnet J.C., Andreoni C., et al. Quantitative analysis of the antigen-specific IFNgamma+ T cell-mediated immune response in conventional outbred pigs: kinetics and duration of the DNA-induced IFNgamma+ CD8+ T cell response. Vet Immunol Immunopathol 2002, 90(3-4):191-201.
50. Steiner E., Balmelli C., Gerber H., Summerfield A., McCullough K. Cellular adaptive immune response against porcine circovirus type 2 in subclinically infected pigs. BMC Vet Res 2009, 5:45.
51. Terpstra C., Bloemraad M., Gielkens A.L. The neutralizing peroxidase-linked assay for detection of antibody against swine fever virus. Vet Microbiol 1984, 9(2):113-120.
52. Hofmann M.A. Construction of an infectious chimeric classical swine fever virus containing the 5'UTR of bovine viral diarrhea virus, and its application as a universal internal positive control in real-time RT-PCR. J Virol Methods 2003, 114(1):77-90.
53. Rau H., Revets H., Balmelli C., McCullough K.C., Summerfield A. Immunological properties of recombinant classical swine fever virus NS3 protein in vitro and in vivo. Vet Res 2006, 37(1):155-168.
54. Ruggli N., Moser C., Mitchell D., Hofmann M., Tratschin J.D. Baculovirus expression and affinity purification of protein E2 of classical swine fever virus strain Alfort/187. Virus Genes 1995, 10(2):115-126.
55. Kalhoro N.H., Veits J., Rautenschlein S., Zimmer G. A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1). Vaccine 2009, 27(8):1174-1183.
56. Bracci L., La Sorsa V., Belardelli F., Proietti E. Type I interferons as vaccine adjuvants against infectious diseases and cancer. Expert Rev Vaccines 2008, 7(3):373-381.
57. Tovey M.G., Lallemand C., Thyphronitis G. Adjuvant activity of type I interferons. Biol Chem 2008, 389(5):541-545.
58. Pichichero M.E. Improving vaccine delivery using novel adjuvant systems. Hum Vaccin 2008, 4(4):262-270.
59. Rizza P., Ferrantini M., Capone I., Belardelli F. Cytokines as natural adjuvants for vaccines: where are we now?. Trends Immunol 2002, 23(8):381-383.
60. Shi Y., Liu C.H., Roberts A.I., Das J., Xu G., Ren G., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res 2006, 16(2):126-133.
61. Tignon M., Kulcsar G., Haegeman A., Barna T., Fabian K., Levai R., et al. Classical swine fever: comparison of oronasal immunisation with CP7E2alf marker and C-strain vaccines in domestic pigs. Vet Microbiol 2010, 142(1-2):59-68.
62. Schweizer M., Matzener P., Pfaffen G., Stalder H., Peterhans E. " Self" and " nonself" manipulation of interferon defense during persistent infection: bovine viral diarrhea virus resists alpha/beta interferon without blocking antiviral activity against unrelated viruses replicating in its host cells. J Virol 2006, 80(14):6926-6935.
63. Hoang-Le D., Smeenk L., Anraku I., Pijlman G.P., Wang X.J., de Vrij J., et al. A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy. Gene Ther 2009, 16(2):190-199.
64. Tovey M.G., Lallemand C. Adjuvant activity of cytokines. Methods Mol Biol 2010, 626:287-309.
65. Shi P.Y., Tilgner M., Lo M.K. Construction and characterization of subgenomic replicons of New York strain of West Nile virus. Virology 2002, 296(2):219-233.
66. Atkins G.J., Fleeton M.N., Sheahan B.J. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med 2008, 10:e33.
67. Polo J.M., Gardner J.P., Ji Y., Belli B.A., Driver D.A., Sherrill S., et al. Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev Biol (Basel) 2000, 104:181-185.